Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Our objective was to determine the interrelationships of interleukin (IL)-6 receptor inhibition with haemoglobin, acute-phase reactants and iron metabolism markers (including hepcidin) in patients with rheumatoid arthritis (RA). METHODS: Data of patients receiving tocilizumab or placebo in the MEASURE study were analysed. We investigated associations at baseline and during tocilizumab treatment among haemoglobin, parameters of haemoglobin and iron homeostasis [ferritin, total iron-binding capacity (TIBC), hepcidin, haptoglobin], IL-6 and acute-phase reactants [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] to identify statistical correlates of rise in haemoglobin level. RESULTS: At baseline, CRP and haptoglobin were inversely correlated (modestly) with haemoglobin levels. After treatment with tocilizumab, CRP, hepcidin, ferritin and haptoglobin levels fell alongside increases in TIBC and haemoglobin. The falls in CRP, hepcidin and haptoglobin levels in the first 2 weeks correlated with a week 12 rise in TIBC and haemoglobin. CONCLUSIONS: Inflammatory anaemia improves in patients with RA treated with tocilizumab. This improvement correlates with the degree of suppression of systemic inflammation, reduction in hepcidin and haptoglobin and increase in iron-binding capacity. These clinical data provide evidence of a role for IL-6 signalling in the inflammatory anaemia of RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Tocilizumab administration also lowered hepcidin and improved anemia in rheumatoid arthritis patients (Isaacs et al., 2013; Song et al., 2013) and in a monkey arthritis model (Hashizume et al., 2010).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Isaacs et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 1×
“Hepcidin acts as a gatekeeper for transmembrane iron transport [3], binding to the cellular iron efflux channel ferroportin, inducing its internalisation and degradation [4].”
BackgroundNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Hepcidin, ferritin and haptoglobin are produced in the liver as acutephase reactants, and their expression is dependent on interleukin-6 (IL-6) signalling [3,7,8].”
BackgroundSmolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399 · cited 2×
“Mean age was slightly higher in this study than in the tocilizumab phase 3 pivotal trials; however, disease characteristics were similar [11-15].”
BackgroundResultEmery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104 · cited 2×
“Mean age was slightly higher in this study than in the tocilizumab phase 3 pivotal trials; however, disease characteristics were similar [11-15].”
BackgroundResultSelf-citationGenovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855 · cited 2×
“Mean age was slightly higher in this study than in the tocilizumab phase 3 pivotal trials; however, disease characteristics were similar [11-15].”
BackgroundResultJones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomšič, M., Alecock, E., Woodworth, T., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105197 · Cited by 797 · cited 2×
“Mean age was slightly higher in this study than in the tocilizumab phase 3 pivotal trials; however, disease characteristics were similar [11-15].”
BackgroundResultTime-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS
Kemna, E., Pickkers, P., Nemeth, E., van der Hoeven, H., & Swinkels, D. (2005) · Blood · doi:10.1182/blood-2005-03-1159 · Cited by 498 · cited 1×
“Hepcidin, ferritin and haptoglobin are produced in the liver as acutephase reactants, and their expression is dependent on interleukin-6 (IL-6) signalling [3,7,8].”
BackgroundKremer, J. M., Blanco, R., Brzosko, M., Burgos-Vargas, R., Halland, A.-M., Vernon, E., Ambs, P., & Fleischmann, R. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30158 · Cited by 409 · cited 2×
“Mean age was slightly higher in this study than in the tocilizumab phase 3 pivotal trials; however, disease characteristics were similar [11-15].”
BackgroundResultIron Sequestration and Anemia of Inflammation
Ganz, T., & Nemeth, E. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.06.001 · Cited by 361 · cited 1×
“; licensee BioMed Central L Commons Attribution License (http://creativec reproduction in any medium, provided the or from macrophage reticuloendothelial stores [3,5].”
BackgroundMihara, M., Kasutani, K., Okazaki, M., Nakamura, A., Kawai, S., Sugimoto, M., Matsumoto, Y., & Ohsugi, Y. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.05.010 · Cited by 328 · cited 1×
“Tocilizumab is a humanised monoclonal antibody that inhibits IL-6 binding to its receptor [9].”
Background
Research works printed but not linked: 2
- McInnes IB, Lee JS, Wu W, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Delles C, Sattar N: MEASURE: a translational, randomized, placebo (PBO)-controlled study to evaluate the effects of tocilizumab (TCZ) on parameters of lipids and inflammation [abstract]. Ann Rheum Dis. 2011, 70 ((suppl)): 73-
- McInnes IB, Lee JS, Wu W, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Delles C, Sattar N: Lipid and inflammation parameters: a translational, randomized placebo-controlled study to evaluate effects of tocilizumab: the MEASURE study. 2011, Chicago, IL: Presented at: 75th Annual Scientific Meeting of the American College of Rheumatology
Cited by
Weiss, G., Ganz, T., & Goodnough, L. T. (2019) · Blood · doi:10.1182/blood-2018-06-856500 · Cited by 1,219
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Nemeth, E., & Ganz, T. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.04.005 · Cited by 401
Hepcidin regulation in the anemia of inflammation
Wang, C.-Y., & Babitt, J. L. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000236 · Cited by 250
Bijlsma, J. W. J., Welsing, P. M. J., Woodworth, T. G., Middelink, L. M., Pethö-Schramm, A., Bernasconi, C., Borm, M. E. A., Wortel, C. H., ter Borg, E. J., Jahangier, Z. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30363-4 · Cited by 248
“Additionally, rapid and sustained control of the acute-phase response might result in a reduction of systemic extra-articular disease manifestations, such as anaemia, 47 osteoporosis, 48 and cardiovascular disease.”
Self-citationInflammatory markers in systemic lupus erythematosus
Aringer, M. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102374 · Cited by 215
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
Perricone, C., Bartoloni, E., Bursi, R., Cafaro, G., Guidelli, G. M., Shoenfeld, Y., & Gerli, R. (2020) · Immunologic Research · doi:10.1007/s12026-020-09145-5 · Cited by 208
Genovese, M. C., Smolen, J. S., Weinblatt, M. E., Burmester, G. R., Meerwein, S., Camp, H. S., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39808 · Cited by 200
“Overall AEs Any AE 13 (26) 20 (40) 23 (46) 29 (58) 25 (50) 17 (35) Any SAE 0 0 2 (4) 1 (2) 3 (6) 2 (4) Any severe AE 0 0 1 (2) 1 (2) 1 (2) 1 (2) Any AE leading to discontinuation 1 (2) 1 (2) 1 (2) 1 (2) 5 (10) 1 (2) Any death† 0 0 0 0 0 0 AEs of special interest Infection 7 (14) 10 (20) 7 (14) 12 (24) 11 (22) 9 (18) S…”
BackgroundThe role of iron in the skin and cutaneous wound healing
Wright, J. A., Richards, T., & Srai, S. K. S. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00156 · Cited by 202
“Isaacs et al. (2013) found that tocilizumab results in an improvement in anemia, reduction in hepcidin/haptoglobin and increase in Frontiers in Pharmacology | Drug Metabolism and Transport July 2014 | Volume 5 | Article 156 | 4 Table 1 | Summary of iron chelators.”
BackgroundInterleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis
Choy, E., & Rose-John, S. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000265 · Cited by 177
“In RA, the role of IL-6 signaling in the development of inflammatory anemia is supported by evidence showing that IL-6R blockade with tocilizumab reduces hepcidin and haptoglobin, as well as CRP, subsequently increasing hemoglobin levels (30).”
BackgroundMarques, O., Weiss, G., & Muckenthaler, M. U. (2022) · Blood · doi:10.1182/blood.2021013472 · Cited by 160
Favalli, E. G. (2020) · Rheumatology and Therapy · doi:10.1007/s40744-020-00219-2 · Cited by 178
Pharmacological Targeting of the Hepcidin/Ferroportin Axis
Sebastiani, G., Wilkinson, N., & Pantopoulos, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00160 · Cited by 127
Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
Biggioggero, M., Crotti, C., Becciolini, A., & Favalli, E. G. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s150580 · Cited by 157
“001 vs placebo) and with the subsequent increase in hemoglobin level (beginning by week 4 and reaching a plateau by week 24).(118) These data have been recently confirmed by an analysis of a large US care database including 153,788 RA patients, showing that patients with anemia treated with TCZ were 86% (OR 1.”
Giacomelli, R., Afeltra, A., Alunno, A., Baldini, C., Bartoloni, E., Berardicurti, O., Carubbi, F., Cauli, A., Cervera, R., Ciccia, F., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.012 · Cited by 139
Katsarou, A., & Pantopoulos, K. (2018) · Pharmaceuticals · doi:10.3390/ph11040127 · Cited by 112
Cai, T., Zhang, Y., Ho, Y.-L., Link, N., Sun, J., Huang, J., Cai, T. A., Damrauer, S., Ahuja, Y., Honerlaw, J., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2287 · Cited by 110
Xu, Y., Alfaro-Magallanes, V. M., & Babitt, J. L. (2020) · British Journal of Haematology · doi:10.1111/bjh.17252 · Cited by 103
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints
Jarlborg, M., & Gabay, C. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155742 · Cited by 104
Catlett, I. M., Hu, Y., Gao, L., Banerjee, S., Gordon, K. B., & Krueger, J. G. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.11.001 · Cited by 86
Hepcidin: Homeostasis and Diseases Related to Iron Metabolism
Reichert, C. O., da Cunha, J., Levy, D., Maselli, L. M. F., Bydlowski, S. P., & Spada, C. (2017) · Acta Haematologica · doi:10.1159/000471838 · Cited by 85
Georgakis, M. K., Malik, R., Li, X., Gill, D., Levin, M. G., Vy, H. M. T., Judy, R., Ritchie, M. D., Verma, S. S., Nadkarni, G. N., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052604 · Cited by 73
Modulation of hepcidin to treat iron deregulation: potential clinical applications
Blanchette, N. L., Manz, D. H., Torti, F. M., & Torti, S. V. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1124757 · Cited by 59
“clinical trial for tocilizumab in rheumatoid arthritis patients (n = 70) further confirmed a reduction in hepcidin and increase in hgb.[108] Consistent in each of these studies was a rapid reduction in hepcidin fol-”
ResultPappas, D. A., John, G. S., Etzel, C. J., Fiore, S., Blachley, T. S., Kimura, T., Punekar, R. S., Emeanuru, K., Choi, J., Boklage, S., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217209 · Cited by 57
Langer, A. L., & Ginzburg, Y. Z. (2017) · Hemodialysis International · doi:10.1111/hdi.12543 · Cited by 52
Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis
Yip, R. M. L., & Yim, C. W. (2019) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001293 · Cited by 58
“Treatment with tocilizumab and sarilumab has been shown to increase hemoglobin levels in RA patients.(19,57,65) Interleukin 6 inhibitors may be a good treatment option to consider RA patients with concomitant anemia.”
BackgroundMethodSerum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis
Sato, H., Takai, C., Kazama, J. J., Wakamatsu, A., Hasegawa, E., Kobayashi, D., Kondo, N., Nakatsue, T., Abe, A., Ito, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66945-3 · Cited by 45
Kay, J., Harigai, M., Rancourt, J., Dickson, C. L., Melby, T. E., Issa, M., de la Torre, I., Isaka, Y., Cardoso, A., Saifan, C., et al. (2020) · RMD Open · doi:10.1136/rmdopen-2020-001370 · Cited by 42
“43 By inhibiting IL-6 receptor signalling, 44 baricitinib may also facilitate iron mobilisation.”
Fisher, A. L., & Babitt, J. L. (2021) · Developmental Dynamics · doi:10.1002/dvdy.372 · Cited by 43
“Treatments targeting inflammatory cytokines, including anti-IL6, anti-IL6 receptor, or anti-TNFα therapy, that have been used to treat patients with rheumatoid arthritis have been shown to be effective in alleviating anemia.(117,118) However, the immunosuppressive properties of these therapies may also lead to adverse…”
BackgroundAnderson, L., Razavi, M., Pope, M. E., Yip, R., Cameron, L. C., Bassini, A., & Pearson, T. W. (2020) · Bioanalysis · doi:10.4155/bio-2019-0278 · Cited by 39
“…range of molecules such as the anti-TNF alpha antibodies infliximab [17] and adalimumab [18] ; TNF inhibitor etanercept [19] ; anti-IL-6 mAbs siltuximab [20] and olokizumab [21] ); anti-IL-6 receptor tocilizumab [22] ; anti-IL-1 β mAb canakinumab [23] ; and IL-1 receptor antagonist anakinra [24] .”
Corominas, H., Alegre, C., Narváez, J., Marras, C., Torrente-Segarra, V., Gómez, M. R., Pan, F. M., Morlà, R., Martínez, F. J. R., Gómez-Centeno, A., et al. (2019) · Medicine · doi:10.1097/md.0000000000015947 · Cited by 35
“The increase in hemoglobin levels could be reflecting declines in hepcidin after TCZ, which previous research has associated with an improvement of inflammatory anemia together with CRP reductions.([31]) Our findings therefore support the beneficial effect of TCZ in decreasing inflammatory activity and improving funct…”
ResultPredictive value of the neutrophil‑to‑lymphocyte ratio and hemoglobin insystemic lupus erythematosus
Yu, H., Jiang, L., Yao, L., Gan, C., Han, X., Liu, R., & Su, N. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6309 · Cited by 35
“Previous studies reported that the hemoglobin level was increased after starting targeted rheumatoid arthritis treatment (22,23), but failed to report longitudinal changes in composite disease activity indices (23).”
Khalaf, W. S., Al-Rubaie, H. A., & Shihab, S. S. (2019) · Hematology Reports · doi:10.4081/hr.2019.7708 · Cited by 43
Taylor, P. C., Feist, E., Pope, J. E., Nash, P. T., Sibilia, J., Caporali, R., & Balsa, A. (2024) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x241283340 · Cited by 39
Emery, P., Durez, P., Hueber, A. J., de la Torre, I., Larsson, E., Holzkämper, T., & Tanaka, Y. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02379-6 · Cited by 28
“Studies have shown that structural damage progression in patients with RA may be inversely linked to baseline haemoglobin (Hb) levels [32–34], which reflect interleukin-6 and C-reactive protein levels [35, 36]; these, in turn, correlate with structural damage progression [11, 37, 38].”
BackgroundClinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis
Padjen, I., Öhler, L., Studenic, P., WOODWORTH, T. G., Smolen, J. S., & Aletaha, D. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.03.001 · Cited by 35
The Role of Iron in Benign and Malignant Hematopoiesis
Sinha, S., Pereira-Reis, J., Guerra, A., Rivella, S., & Duarte, D. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8155 · Cited by 30
Unravelling the broader complexity of IL-6 involvement in health and disease
Jenkins, R. L., Hughes, S. T. O., Figueras, A. C., & Jones, S. A. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155684 · Cited by 26
“Mitochondrial Ca(2)(+) and membrane potential, an alternative pathway for Interleukin 6 to regulate CD4 cell effector function.”
BackgroundWang, C., Fang, Z., Zhu, Z., Liu, J., & Chen, H. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.05.002 · Cited by 30
Goodman, S. M., & Figgie, M. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2015.09.004 · Cited by 26
Atallah, B., Nekidy, W. S. E., Mallah, S. I., Cherfan, A. J., AbdelWareth, L., Mallat, J., & Hamed, F. (2020) · Thrombosis Journal · doi:10.1186/s12959-020-00236-9 · Cited by 23
Meyer, A., Yan, S., Golumba-Nagy, V., Esser, R. L., Barbarino, V., Blakemore, S. J., Rusyn, L., Nikiforov, A., Seeger‐Nukpezah, T., Grüll, H., et al. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102726 · Cited by 22
Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
Lazzerini, P. E., Capecchi, P. L., Guidelli, G. M., Selvi, E., Acampa, M., & Pasini, F. L. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s99898 · Cited by 22
“The severity of anemia of chronic diseases in RA strictly correlates with IL-6 levels, while TCZ treatment induces a rapid increase in hemoglobin levels as a result of an inhibitory effect on hepcidin production.(41,52) In RA patients, the prevalence of CVD is significantly increased, accounting for ~50% of premature…”
Pathophysiology of Iron Homeostasis during Inflammatory States
Cherayil, B. J. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.07.015 · Cited by 28
“Nevertheless, serum or urine hepcidin levels have been shown to be significantly elevated in a number of human inflammatory conditions, including IBD, rheumatoid arthritis, malaria, human immunodeficiency virus infection and neonatal sepsis (19-22,44-47).”
BackgroundTakayasu arteritis: Prevalence and clinical presentation in Switzerland
Gloor, A. D., Chollet, L., Christ, L., Cullmann, J. L., Bonél, H., & Villiger, P. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250025 · Cited by 20
“Tocilizumab blunts the acute phase response [20].”
BackgroundInfluentialNakayama, Y., Watanabe, R., Yamamoto, W., Ebina, K., Hirano, T., Kotani, T., Shiba, H., Katayama, M., Son, Y., Amuro, H., et al. (2023) · Lara D. Veeken · doi:10.1093/rheumatology/kead299 · Cited by 20
Interleukin-6 May Not Affect Bone Resorption Marker CTX or Bone Formation Marker P1NP in Humans
Lehrskov, L. L., Kjeldsen, S. A. S., Lyngbæk, M. P. P., Chirstensen, R. H., Wedell‐Neergaard, A., Soederlund, L., Jørgensen, N. R., Krogh‐Madsen, R., Albrechtsen, N. J. W., & Ellingsgaard, H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa093 · Cited by 23
“In the long-term study, the efficiency of tocilizumab was evaluated by reduced levels of high-sensitive C-reactive protein [19,30,31].”
BackgroundDiagnostic value of hemoglobin and neutrophil-to-lymphocyte ratio in Behcet Disease
Zhang, Z., Su, Q., Zhang, L., Yang, Z., Qiu, Y., & Mo, W. (2019) · Medicine · doi:10.1097/md.0000000000018443 · Cited by 18
“Previous studies reported that low HB levels was significantly related to the activity of RA([22,23]) and the HB level was increased after starting targeted RA treatment.([24]) Besides, Yu et al proved that the HB level of SLE patients is significantly lower than that of the healthy control group, which can be used as…”
BackgroundLeil, T. A., Lu, Y., Bouillon‐Pichault, M., Wong, R. L., & Nowak, M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2023 · Cited by 17
“This is likely due to the disproportionate effect of IL-6R inhibition on acutephase inflammation, resulting in a much greater effect on either ESR or CRP.39 While there are qualitative similarities between DAS28 and ACR scores, as reflected by the similar results of the DAS28 MBMA reported here and prior analyses base…”
ResultInfluentialIron metabolism and arthritis: Exploring connections and therapeutic avenues
Zhuo, D., Xiao, W., Tang, Y.-L., Jiang, S., Geng, C., Xie, J., Ma, X., Zhang, Q., Tang, K., Yu, Y., et al. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003169 · Cited by 19
“[18] And, this treatment is believed to protect against ACD in various diseases, including RA.”
BackgroundLiu, X., Li, L., Wang, Q., Jiang, F., Zhang, P., Guo, F., Liu, H., & Huang, J. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816646 · Cited by 18
“IL-6 inhibition targeting IL-6R has shown beneficial effects not only within the joint, but also in the extraarticular manifestations of RA in several clinical studies (8, 9).”
BackgroundDevelopment of a model for anemia of inflammation that is relevant to critical care
Boshuizen, M., van Bruggen, R., Zaat, S. A. J., Schultz, M. J., Aguilera, E., Motos, A., Senussi, T., Idone, F. A., Pelosi, P. P., Torres, A., et al. (2019) · Intensive Care Medicine Experimental · doi:10.1186/s40635-019-0261-2 · Cited by 13
Tortora, C., Paola, A. D., Creoli, M., Argenziano, M., Martinelli, M., Miele, E., Rossi, F., & Strisciuglio, C. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac073 · Cited by 12
The interleukin-6-hepcidin-hemoglobin circuit in systemic lupus erythematosus flares
Indrakanti, D., Alvarado, A. S., Zhang, X., Birmingham, D. J., Hinton, A. M., & Rovin, B. H. (2016) · Lupus · doi:10.1177/0961203316659153 · Cited by 15
Boshuizen, M., Binnekade, J. M., Nota, B., van de Groep, K., Cremer, O. L., Horn, J., Schultz, M. J., van Bruggen, R., & Juffermans, N. P. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000497123 · Cited by 12
Anemia of chronic diseases: current state of the problem and perspectives
Mironova, O. I., & Panferov, A. S. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.12.201984 · Cited by 12
An Overview of Nutritional Aspects in Juvenile Idiopathic Arthritis
Zandonadi, R. P. (2022) · Nutrients · doi:10.3390/nu14204412 · Cited by 10
“In addition, IL-6 induces the liver production of peptide that inhibits iron absorption in the intestine and releases recycled iron from the macrophages [73,74].”
BackgroundTocilizumab Treatment Effect on Iron Homeostasis in Severe COVID-19 Patients
Guz, D., Gafter‐Gvili, A., Lev, N., Levin, G. S., & Lev, S. (2022) · Acta Haematologica · doi:10.1159/000522307 · Cited by 10
Wang, Z., Hou, Y., Cai, L., & Chen, Y. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01534-4 · Cited by 9
Li, Z., Geng, M.-Y., Dou, S.-R., Wang, X., Zhang, Z., & Chang, Y. (2022) · Life · doi:10.3390/life12071025 · Cited by 13
Rubbert‐Roth, A., Fürst, D. E., Fiore, S., Praestgaard, A. H., Bykerk, V. P., Bingham, C. O., Charles‐Schoeman, C., & Burmester, G. R. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02891-x · Cited by 13
Suzuki, S. O., Nakano, S., Ando, S., Matsudaira, R., Kanai, Y., Yamanaka, K., & Takasaki, Y. (2016) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2016.09.004 · Cited by 9
Serum Hepcidin Is Increased in ANCA-Associated Vasculitis and Correlates With Activity Markers
Přikryl, P., Hrušková, Z., Konopásek, P., Hladinová, Z., Tesař, V., & Vokurka, M. (2018) · Physiological Research · doi:10.33549/physiolres.933765 · Cited by 11
“Treatment of RA patients by tocilizumab improved anemia and led to the reduction of hepcidin levels (Isaacs et al. 2013; Song et al. 2013).”
BackgroundSong, J., Zhang, Y., Li, A., Peng, J., Zhou, C., Cheng, X., Wu, Y., Zhao, W., Zong, Z., Wu, R., et al. (2024) · Medicine · doi:10.1097/md.0000000000038471 · Cited by 8
“[21] The dietary inflammation index (DII) [22] is a literature-derived method to assess the potential inflammatory levels of our daily diet.”
MethodCOVID-19 as part of the hyperferritinemic syndromes: is there a role for iron depletion therapy?Preprint
Perricone, C., Bartoloni, E., Bursi, R., Cafaro, G., Guidelli, G. M., Shoenfeld, Y., & Gerli, R. (2020) · doi:10.22541/au.158880283.34604328 · Cited by 8
El-Shafey, A. M., Kamel, L. M., Fikry, A. A., Nasr, M. M., & Galil, S. M. A. (2020) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-020-00006-5 · Cited by 8
Galushko, E. A. (2014) · PubMed · Cited by 7
Park, K., Jin, H., Cho, Y., Kang, J.-H., Jung, H., Kang, J., Kim, J.-E., Yim, Y., Lee, J., Lee, K.-E., et al. (2016) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2016.23.1.37 · Cited by 7
“Consistent with previous studies [16,17], these findings”
BackgroundResultInfluentialSelf-citationKarásková, E., Volejníková, J., Holub, D., Véghová-Velgáňová, M., Špenerová, M., Mihál, V., & Pospı́šilová, D. (2019) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.14593 · Cited by 7
Sánchez‐Rovira, P., Chica, G. P., Granados, A. L. O., Aguilar-García, J. A., Díaz-Beltrán, L., Gálvez-Montosa, F., García‐Verdejo, F. J., Caro, N. L., Blanco, C. Q., Fernández-Navarro, M., et al. (2020) · Medicine · doi:10.1097/md.0000000000026533 · Cited by 6
“TCZ therapy did not change the level of ferritin, even though it has been reported that it can be reduced in patients with rheumatoid arthritis.([32]) However, the IL-6 level increase matches the elevated serum levels found in rheumatoid arthritis patients that were treated with TCZ, which is explained by the inhibiti…”
BackgroundSuzuki, S. O., Nakano, S., Ando, S., Matsudaira, R., Kanai, Y., Yamanaka, K., & Takasaki, Y. (2016) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2016.07.004 · Cited by 6
Olokizumab for treatment of rheumatoid arthritis
Moiseev, S. V., Novikov, P. I., Chebotareva, N. V., Gulyaev, S. V., Bulanov, N. M., Shevtsova, T., & Маратовна, Щ. Е. (2021) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2021-2-67-74 · Cited by 5
Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
Szabó, R., Petrișor, C., Bodolea, C., Dobre, V., Trancă, S., Clichici, S. V., Szabo, I., Melinte, R. M., & Mocan, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020646 · Cited by 5
“This could have a positive impact on the occurrence of anemia and the need for transfusions [31,32].”
BackgroundShadick, N. A., HAGINO, O. R., Praestgaard, A. H., Fiore, S., Weinblatt, M. E., & Burmester, G. R. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03068-w · Cited by 4
“3 g/dL) has been reported after tocilizumab treatment [13, 14].”
BackgroundReichert, C. O., da Cunha, J., Levy, D., Maselli, L. M. F., Bydlowski, S. P., & Spada, C. (2017) · InTech eBooks · doi:10.5772/intechopen.69507 · Cited by 5
Weiler, S., & Nairz, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627223 · Cited by 4
“Therefore, tocolizumab ameliorates disease activity and lowers circulating hepcidin levels in rheumatologic diseases (96, 97).”
BackgroundThe role of IL-6 in rheumatoid arthritis comorbidity and implications for therapy
Monaco, F., Dimonte, S., & Jones, S. A. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120136 · Cited by 4
“These findings were corroborated by Isaacs and colleagues in 2013, who reported significant improvements in haematological markers in RA patients treated with tocilizumab, providing further evidence that IL-6 signalling plays a pivotal role in the pathogenesis of RA-associated anaemia [159].”
Anemia and Transfusion in Infective Endocarditis
Alberts, T., Eberl, S., van der Vaart, T. W., Boekholdt, S. M., & Hermanns, H. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm33394 · Cited by 5
“IL-6 inhibitors, like tocilizumab, have shown to inhibit hepcidin proliferation and improve anemia in autoimmune diseases with inflammation such as rheumatoid arthritis and Castleman’s disease [94–96].”
Davies, A., Devlin, P., Dugan, C., Richards, T., & Miles, L. F. (2023) · Transfusion · doi:10.1111/trf.17274 · Cited by 4
“This was associated with a fall in ferritin levels at 4 weeks, sustained for the duration of the study.(38) In another study, IL-6 inhibition induced similar reductions in hepcidin and increased transferrin compared with placebo amongst patients with rheumatoid arthritis over 16 weeks.”
BackgroundResultTargeting IL-6 Signaling Pathways for Musculoskeletal Disorders Treatment: Risks and Benefits
Shanshal, A. M., Aljorani, R. H., & Hussain, S. A. (2023) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v4i.101 · Cited by 3
Mechanisms, mishaps and manipulation of iron uptake
Bennett, C., & Pasricha, S. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000237 · Cited by 1
Matsushita, S., Sada, K., Manabe, A., Kashihara, E., Tagawa, S., Akebo, H., Miyake, H., Sada, R. M., & Hatta, K. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9487-22 · Cited by 1
“This may have been a downstream effect of TCZ, which suppresses CRP, hepcidin, and ferritin via IL-6 and the Janus kinase-signal transducer/activator of transcription (JAK-STAT) pathway (6, 7).”
BackgroundInvestigation of a raised ferritin—hereditary haemochromatosis or not?
Gurumurthy, G., Brown, R., & Thachil, J. V. (2025) · QJM · doi:10.1093/qjmed/hcaf330 · Cited by 1
Genedy, M. M., Shabana, A. A. E. H., Elghzaly, A. A., & Bassiouni, S. A. R. A. K. (2024) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-024-00276-3 · Cited by 5
“The interrelationships of interleukin (IL)-6 receptor inhibition with iron metabolism markers including hepcidin have been determined in patients with RA and hepcidin levels fell alongside increases in hemoglobin after treatment with tocilizumab [38].”
BackgroundНовые подходы к лечению анемии хронических заболеваний
Будневский, А. В., Сергеевич, О. Е., Воронина, Е. В., Лабжания, Н. Б., & Жусина, Ю. Г. (2018) · Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» · doi:10.25557/0031-2991.2018.03.106-112 · Cited by 1
Transferrin as a Possible Treatment for Anemia of Inflammation in the Critically Ill
Boshuizen, M., Bassi, G. L., & Juffermans, N. P. (2019) · Annual update in intensive care and emergency medicine · doi:10.1007/978-3-030-06067-1_45 · Cited by 1
A deep dive into future therapies for microcytic anemias and clinical considerations
Rodrigues, F., Coman, T., Fouquet, G., Côté, F., Courtois, G., Maciel, T. T., & Hermine, O. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2206556 · Cited by 1
Efficacy of Tocilizumab For Treatment of Severe COVID-19 Pneumonia: More Evidence Is Needed
Oliveira, B. D., & Mallat, J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1284 · Cited by 1
“We agree and applaud the decision to use serial C-reactive protein measurements to assess the efficacy of interleukin-6 receptor blockade, even if these results are not surprising since that is the established function of tocilizumab [4].”
Background[Advances on diagnosis and treatment of anemia of inflammation].
Wang, Y. S., & Zhang, F. K. (2018) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2018.09.017
“[32] Isaacs JD, Harari O, Kobold U, et al.”
BackgroundLaboratory assessment of systemic lupus erythematosus
Alhussain, A. H., Alquwayi, W. A., Alkuwaiti, Y. A. A., Almehainy, A. M., & Alkhathami, A. A. (2020) · International Journal of Health Sciences · doi:10.53730/ijhs.v4ns1.15215 · Cited by 1
“Although a direct correlation based on serum levels has not been established in SLE [24], a larger study in rheumatoid arthritis (RA) suggested a clear relationship in that context [25, 26, 27].”
BackgroundEmery, P., Durez, P., Hueber, A. J., de la Torre, I., Larsson, E., Holzkämper, T., & Tanaka, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13521127
Emery, P., Durez, P., Hueber, A. J., de la Torre, I., Larsson, E., Holzkämper, T., & Tanaka, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13521115
Rubbert-Roth, A., Furst, D. E., Fiore, S., Praestgaard, A. H., Bykerk, V., Bingham, C. O., Charles‐Schoeman, C., & Burmester, G. (2022) · Figshare · doi:10.6084/m9.figshare.20652304
Emery, P., Durez, P., Hueber, A. J., de la Torre, I., Larsson, E., Holzkämper, T., & Tanaka, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13521112
Emery, P., Durez, P., Hueber, A. J., de la Torre, I., Larsson, E., Holzkämper, T., & Tanaka, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13521124
Shadick, N. A., HAGINO, O. R., Praestgaard, A. H., Fiore, S., Weinblatt, M. E., & Burmester, G. (2023) · Figshare · doi:10.6084/m9.figshare.23240023
Emery, P., Durez, P., Hueber, A. J., de la Torre, I., Larsson, E., Holzkämper, T., & Tanaka, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13521109
Emery, P., Durez, P., Hueber, A. J., de la Torre, I., Larsson, E., Holzkämper, T., & Tanaka, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13521121
Rubbert-Roth, A., Furst, D. E., Fiore, S., Praestgaard, A. H., Bykerk, V., Bingham, C. O., Charles‐Schoeman, C., & Burmester, G. (2022) · Figshare · doi:10.6084/m9.figshare.20652301
Emery, P., Durez, P., Hueber, A. J., de la Torre, I., Larsson, E., Holzkämper, T., & Tanaka, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13521118
Metadata
- Authors
- Isaacs, J. D., Harari, O., Kobold, U., Lee, J. S., & Bernasconi, C.
- Affiliations
- Newcastle University (GB)
- F. Hoffmann-La Roche AG (CH)
- Corresponding author
- Isaacs, John D
- Venue
- Arthritis Research & Therapy
- Published
- 2013-12-02
- Volume
- 15
- Issue
- 6
- Pages
- R204-R204
- ISSN
- 1478-6354 (ISSN-L)
- PMC
- PMC3978585
- OpenAlex
- W2114448779
- Cited by
- 105
- References
- 17
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 10 · 2021: 18 · 2020: 16 · 2019: 10 · 2018: 9 · 2017: 7 · 2016: 9 · 2015: 3 · 2014: 3
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Arthritis Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- tocilizumab, rheumatoid arthritis, IL-6 receptor inhibition, hepcidin, haptoglobin, ferritin, total iron binding capacity, iron metabolism, hemoglobin, C-reactive protein, acute phase proteins, systemic inflammation
- MeSH terms
- Adult, Aged, Anemia, Arthritis, Rheumatoid, Double-Blind Method, Female, Haptoglobins, Hemoglobins, Humans, Male, Middle Aged, Signal Transduction, Biomarkers, Interleukin-6, Antibodies, Monoclonal, Humanized, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.